Paradigm Medical Announces the Introduction of the Paravue 300 and Surveyor 500 at 2009 American Academy of Ophthalmology in San Francisco
Published: Dec 15, 2009
SALT LAKE CITY, UT--(Marketwire - December 15, 2009) -
Paradigm Medical Industries
These are the first two products Paradigm is introducing from its Italian partner, Costruzione Strumenti Oftalmici (C.S.O.), with additional products scheduled for 2010. The Paravue 300 and Surveyor 500 fill a gap created by an earlier decision to discontinue manufacturing the CT 200 (corneal topographer), which was outdated.
"The AAO attendees response to the Paravue 300 and Surveyor 500 was very impressive and will serve as a springboard for Paradigm to continue to develop, locate and introduce new and innovative products to the ophthalmic marketplace," said Stephen Davis, Paradigm President and CEO.
Paradigm Medical also announced the relocation of its corporate office to 4273 South 590 West, Salt Lake City, Utah 84123. All phone numbers will remain the same. "This move will provide Paradigm with a more suitable facility that meets its current manufacturing and operational needs and reduces its overhead cost," said Mr. Davis.
About Paradigm Medical Industries, Inc.
Headquartered in Salt Lake City, Utah, Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes ophthalmic diagnostic instruments and related products for early glaucoma detection and other eye disorders. Paradigm has the only patented technology utilizing photon laser for cataract removal. The Company is poised to capture a niche market within the glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States, as well as internationally.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
For more information, please visit: www.paradigm-medical.com
Paradigm Medical Industries, Inc.
President and CEO